DocumentsDate added
Research article:-Paediatrics
Caroline .A. Okoli1* & Gregory .E. Anekwe2
1Department of Paediatrics, University of Jos, Nigeria. 2Department of Biochemistry University of Jos, Nigeria.
Abstract: Background: In Nigeria, there is a very limited documentation on nutrient composition of fish species and the Africa catfish in particular. There is no documented data on identification of coenzyme Q10 in Africa catfish (Clarias gariepinus) liver oil. Africa catfish (Clarias gariepinus) is more common and cheaper than some other fishes rich in coenzyme Q10. Thus, identifying this nutrient in this fish could help in proper dietary planning, thereby ensuring better health. Method and Result The lipid fractions of the purified supernatant from centrifugation of 250g of 400 Africa catfish livers in 0.02M phosphate buffer pH7.0 were extracted using chloroform-methanol solution and purified by Folch wash giving a concentration of 100μg of lipids per μl. The lipid fraction was fractionated into neutral lipid and polar lipids by silicic acid chromatography and saponified using petroleum ether layer. Alumina column chromatography was used to fractionate and isolate the non-saponifiable parts including coenzyme fraction and their provisional identification was achieved by silica gel TLC and comparing of Rf values with that of reference standards after staining with iodine. The Rf of coenzyme fraction was 0.19.Confirmatory identification of coenzyme was by spectrophotometer. Coenzyme fraction and ubiquinone standard had peak absorption at 328nm and the concentration of ubiquinone in the coenzyme fraction was 0.6mg/ml Conclusion: Coenzyme Q10 is present in the liver oil of Africa catfish (Clarias gariepinus).
Key words: Co-enzyme Q10, ubiquinone Q10, Africa catfish (Clarias gariepinus), liver oil, Nigeria.
References:
1. Palamakula A and Khan M. Evaluation of cytotoxicity of oils used in coenzyme Q10 self-emulsifying drug delivey systems (SEDDS). Int J. Pharm 2004; 273, 63-73
2.Kang B.K , Lee J.S, Chon S.K, Jerg S.Y, Yuk S.H.Development of self micro-emulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J. Pharm 2004;274;65-73.
3. Clarias gariepinus.( 2012): [Cited: October 20, 2012]. Available from: www.wikipedia.org
4. Osibona AO, Kusemiju K and Akande GR . Proximate composition and fatty acids profile of the Africa cat fish Clarias gariepinus. actaSATECH; 2006; 3(1): In Press
5.Exler J. Composition of foods: Finfish and shellfish products. US Department of Agriculture , Agriculture handbook. 1987;Pp9-13.
6.Chandrashekar.K.Proximate composition , amino acids , mineral and trace element content of the edible muscle of 20 Indian fish species. Journal of Food Composition and Analysis 1993; 6(2):195-200.
7. Eun J.B , Chung H.J and Hearnsberger J.O.Chemical composition and microflora of channel catfish (ictaiurus punctatus) roe and swim bladder. Journal of Agricultural and Food chemistry 1994; 42(3):714-7.
8.Wanasundana U.W and Shahidi .F. Lipase –assisted concentration of n-3 polyunsaturated fatty acids in acylglycerols from marine oils. Journal of the American oil chemists society 1998; 75(8):945-51.
9.Uauy R and Valenzuela A. Mawine oils : the health benefits of n-3 fatty acids. Nutrtion (2000);6(7/8):680-4.
10.Schanfeldt H.C.Food composition program of AF-RO FOODS. Journal of food composition and Analysis 2002; 15:473-9.
11.Kieburt K.[the Huntington study group]. A randomized placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s diseases. Neurology 2001; 57,397-404.
12. Overvad K, Diamant .B, Holm L, Holmnoa, Mortensensen S.A, Stender .S. Coenzyme Q10 in health and disease. Eur J Clin Nutr 1999;53(10), 704-70.
13. Shultz C.w, Oakes D, Kieburtz K, Beal F.L., Haas R., Plums S.J, Juncos J.L., Nutt J., Shoulson I. Carter J., Kompoliti K., Perlmutter J.S., Reich S., Stern M, Watts R.C, Kurlan .R., Morlho .E., Harrison .M., Lew .M and the Parkinson study group, 2002, effects of coenzyme Q10 in early Parkinson Disease. Arch Neurol; 59: 1541-50.
14. Mahendra K., Murthy Y.L.N, Narasimha C.V and Krishnala B.M. Determination of ubiquinone Q10 (coenzyme Q10) and its synthesis related impurities by High Performance Liquid chromatography (HPLC) and mass spectrometry (MS). J. Pharm tech Res 2011; 3(3) 1467-7.
15. Fish liver oil- nature’s tool for fighting inflammation. (2011). [ Cited: April 4, 2012 ]. Available from: www.fattyacidshub.com/fishoil/cod-codliver.
16. Blinznakov E.G. From sharks to coenzyme Q10. Adv Exp Med Biol. 1976; 73 PT-A: 441-50
17. Anekwe G.E. Effects of vanadium peroxide on the incorporation of [2-14C]- acetate into fungal lipids. Physiol. Plant 1976; 38:305-6.
18.Fish J, Holz (Jr) G.G, Beach D.M, Owen .E and Anakwe G.E . The cyclopropene fatty acid of Trypanosomiasis. Mol and Biochemical Parasitology 1981; 3, 103-15.
19. Folch J. Lees. M and Sloane Stanley G.H. A sample method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem 1957; 226,497-509.
20. Anekwe G.E and Lee L.L characterization of sulfated cerebrosides from the mycelia of Glomerella cingulated. Physio. Plant. 1973; 29, 134-6.
21. Beach D.H, Mueller J.F and Holz (Jr) G.G . Benzoquinones in stages of the life-cycle of the cestode, Spiromatra mansonoides. Mol and Biochemical Parasitology 1980;1, 269-78.
22. Anekwe G.E. Influence of vanadium sulphate on lipid biosynthesis by rat liver microsomes and soluble enzyme fraction. IRCS Medical Science; Metabolism and Nutrition Pharmacology 1981; 9; 211-2. Also in journal of Medicinal and pharmaceutical Marketing.6(5),295-6.
23. Mangold H.K and Malina D.C.Fractionation of fats, oils and waxes on thin layer of silicic acid. J. Am Iol Chemists’ Soc.1960; 37, 383-5.
24. Anekwe G.E Lipids. In: Concise Biochemistry. 3nd edn. Published by University Press Nigeria. 2011;Pp 45-52,113.
25.KanekaQ10 products: dietary supplements.(2011). [Cited: April 4, 2012]. Available from: www.kanekaq10.com/.
26.Cunningham N.F and Morten R.A. Unsaponifiable constituents of liver; ubiquionone and substance SC in various species. Biochem. J.1959; 72, 92-99.
27.Yamada . M (1972). New observations on the lipids of Aquatic origin. Mer. Fac. Fish. Hokkaido Univ. XIX ½,35-137.
28. Daniel R.M and Redfearn (1966). The alleged absence of ubiquionone from elasmobranchs. Biochem. J. 100; 80.
29.Diplock A.T and Haslewood G.A. D .The ubiquinone content of animal tissues. A survey of the occurrence of ubiquinone in vertebrates. Biochem. J 1967; 104, 1004-9.
Copyright © 2013 Caroline. A Okoli & Gregory. E Anekwe. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
An Informed view:- Periodontology
Kamath Deepa G1*& Nayak Sangeeta U2
1Additional Professor, 2Assistant Professor, Department of Periodontology, Manipal College of Dental Sciences ,Mangalore, Manipal University, India.
Abstract:- Dentinal hypersensitivity is characterized by a short, sharp pain in response to various stimuli. It is more commonly seen in adults in the 20- to 40-year-oldage group, has several etiological factors. Gingival recession and enamel loss both contribute to the prevalence of this condition, resulting in the exposure of dentin. Dentinal hypersensitivity is believed to occur due to the movement of fluid within the dentinal tubules occuring in response to thermal, chemical, tactile and evaporative stimuli, in accordance with Brännström’s Hydrodynamic Theory. Treatment options include in-office procedures and home use, self-applied products that are aimed at either occluding he dentinal tubules or preventing neural transmission and there by blocking the pain response.
Key words:- Dentinal Hypersensitivity, Recession, Pain, Potassium nitrate.
References:- 1.Addy M, Urquart E.: Dentine hypersensitivity: its prevalence, aetiology and clinical management. Dental Update 1992; 19: 407-12.
2.Walter AP: Dentine hypersensitivity: A review. J Contemp Dent Practice 2005;6:2:1-10
3.Chabanski MB, Gillam DG :Aetiology, prevalence and clinical features of cervical dentinesensitivity. J Oral Rehabil 1997; 24, 15-9.
4.Gillam DG, Orchardson R. Advances in the treatment of root dentin sensitivity: mechanismsand treatment principles. Endod Topics 2006; 13, 13-33.
5.Isabel C. C. M. Port, Ana K. M. Andrade and Marcos A. J. R. Montes:Journal of Oral Science, 2009; 51( 3), 323-32.
6.Orchardson R, Gillam DG. Managing dentinhypersensitivity. J Am Dent Assoc 2006;137, 990-8.
7.Addy M.: Etiology and clinical implications of dentine hypersensitivity. Dent Clin No Amer 1990;34:503-14.
8. Scherman A, Jacobsen PL. Managing dentin hypersensitivity: what treatment to recommend to patients. J Am Dent Assoc 1992; 123:57-61.
9. Jacobsen PL, Bruce G. Clinical dentin hypersensitivity: understanding the causes and prescribing a t reatment. J. Contemporary Dent Practice 2001;2(1):1-8.
10. Canadian Advisory Board on Dentin Hypersensitivity: Consensus-based recommendations for the diagnosis and management of dentin hypersensitivity. J Can Dent Assoc 2003;69(4): 221-6.
11.Poulsen S, Errboe M, Hovgaard O, et al. Potassium nitrate toothpaste for dentine hypersensitivity(Review). The Cochrane Collaboration 2004, Issue 4, Wiley Publisher .1-11.
12. Nagata T, Ishida H, Shinohara H, et al. Clinical evaluation of a potassium nitrate dentifrice for thetreatment of dentinal hypersensitivity. J Clin Peridontol 1994;21 (3):217-21.
13. Schiff T, Dotson M, Cohen S, et al. Efficacy of a dentifrice containing potassium nitrate, soluble pyrophosphate, PVM/MA copolymer, and sodium fluoride on dentinal hypersensitivity: a twelve-week clinical study. J Clin Dent 1994;5 Spec No: 87-92.
14. Silverman G. The sensitivity reducing effect of brushing with a potassium nitrate-sodium monofluorophosphate dentifrice. CompendContinEduc Dent 1985;6(2):z131-3.
15. Schiff T, Santos MD, Laffi S, et al. Efficacy of a dentifrice containing 5% potassium nitrate and1500 ppm sodium monofluorphosphate in a precipitated calcium carbonate base on dentinal hypersensitivity. J Clin Dent 1998;9(1):22-5.
16.Orchardson R, Gillam DG. The efficacy of potassium salts as agents for treating dentin hypersensitivity. J of Orofacial Pain 2000;14:9-19.
17.Thrash WJ, Dodds WJ, Jones DL. The effect of stannous fluoride on dentinal hypersensitivity.International Dent J 1994;44:107-18. Suppl 1.
18.Suge T, Kawasaki A, Ishikawa K, Matsuo T, Ebisu S. Effect of ammonium hexafluorosilicate ondentin tubule occlusion for the treatment of dentinhypersensitivity. Am J Dent 2006; 19, 248-52.
19.Kern DA, McQuade MJ, Scheidt MJ, Hanson B, VanDyke TE. Effectiveness of sodium fluoride on tooth hypersensitivity with and without iontophoresis. J Periodontol 1989; 60:386-9.
20.Mahmoud AS, Almas K, Dahlan AA. The effect of propolis on dentinal hypersensitivity andlevel of satisfaction among patients from a universityhospital Riyadh, Saudi Arabia. Indian J Dent Res 1999;10: 130-7.
21.Sauro S, Gandolfi MG, Prati C, Mongiorgi R. Oxalate-containing phytocomplexes as dentine desensitizers: an in vitro study. Arch Oral Biol 2006; 51,655-64.
22.Kimura Y, Wilder-Smith P, Yonaga K, Matsumoto K. Treatment of dentine hypersensitivity by lasers: a review. J ClinPeriodontol2000; 27:715-21.
23.Pashley DH (2000) Potential treatment modalities. for dentine hypersensitivity: in-office products. In:Tooth wear and sensitivity: clinical advances inrestorative dentistry 2000, Addy M, EmberyG,Edgar WM, Orchardson R eds, Martin Dunitz,London 2009;51(3):351-65.
24. McCarthy D, Gillam DG, Parson DJ. In vitro effects of laser radiation on dentine surfaces. J Dent Res 1997;76, Special issue, 233.
25.Gandolfi MG, Farascioni S, Pashley DH, GiorgioG, Prati C. Calcium silicate coating derivedfrom Portland cement as treatment for hypersensitivedentine. J Dent 2008;36: 565-78.
26.Walsh LJ, Wang WS, Calar A, Devani C, Tran KK, Hall A.Effect of CCP–ACP versus potassium nitrate on cervicaldentinal hypersensitivity. J Dent Res 2006; 85.
27.Forsback AP, Areva S, Salonen JI. Mineralization of dentininduced by treatment with bioactive glass S53P4 in vitro.ActaOdontolScand 2004; 62 : 14-20.
28.Samruddhi D Pol, Mukesh Chute, TanayGunjikar, JyotiJonnala, Dilip G Pol: Advances in the Treatment of Dentinal Hypersensitivity 2011; 5(12):1249-50.
29.Frechoso SC, Menendez M, Guisasola C, Arregui I, Tejerina JM, Sicilia A. Evaluation of the efficacy of two potassium nitrate bioadhesive gels (5% and 10%) in the treatment of dentine hypersensitivity. A randomised clinical trial. J ClinPeriodontol 2003;
30 : 315-20. 30. Sanjay Miglani, et al. Dentin hypersensitivity: Recent trendsin management. Journal of Conservative Dentistry 2010: 13(4).
Copyright © 2013 Kamath Deepa G & Nayak Sangeeta U. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case report:-
Agrawal C Alok1 & Sharma Saurabh2*
1Associate Professor,Orthopaedics, MAMS BMC,Sagar,Madhya Pradesh,India.
2Assistant Professor, Peoples Medical College ,Bhopal, Madhya Pradesh,India.
References:-
1.Hibbs RA. An operation for progressive spinal deformities.N Y Med 1911;121:1013.
2.Albee FH. Transplantation of a portion of the tibia into the spine for Pott’s disease. JAMA 1911;57:855.
3.Long DM. Failed back surgery syndrome. Neurosurg Clin N Am 1991;2(4):899–919.
4.Slone RM, McEnery KW, Bridwell KH, Montgomery WJ. Fixation techniques and instrumentation used in the thoracic, lumbar and lumbosacral spine. Radiol Clin North Am 1995;33(2):233–6.
5.Lonstein JE, Denis F, Perra JH, Pinto MR, SmithMD, Winter RB. Complications associated with pedicle screws. J Bone Joint Surg Am 1999;81: 1519–28.
6.Babat LB, McLain RF, Bingaman W, Kalfas I,Young P, Rufo-Smith C. Spinal surgery in patients with Parkinson’s disease: construct failure and progressive deformity. Spine 2004;29(18):2006–12.
7.Phillip M. Young, Thomas H. Berquist, Laura W. Bancroft,Jeffrey J. Peterson. Complications of Spinal Instrumentation. RadioGraphics 2007; 27:775–89.
Copyright © 2013 Agrawal C Alok & Sharma Saurabh., This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article:-Orthopaedics
Salgia Anil1*, Agarwal Tushar2,Biswas S. K3,Sanghi Sahil4 & Sachdev Abhishek4.
1Professor,2Assistant Professor,3Professor & HOD,4Resident,Department of Orthopaedics, Padmashree Dr. D. Y. Patil Medical College, Hospital & Research Centre, Pimpri, Pune 411018.India.
Abstract: Background: Chronic shoulder pain is pain that lingers more than three months continuously or intermittently associated with restricted range of movement. Shoulder pain with restriction of movements is commonly seen in inflammatory and degenerative disease of shoulder joint. Suprascapular nerve block has shown promising results in limited trials in reducing shoulder pain and improvement in range of movements. No large randomized placebo controlled trials examining the efficacy of suprascapular nerve block for shoulder pain using bupivacaine/bupivicane+methyl prednisolone comparing pain and improvement in range of movement is available. Aims & objectives: To assess and compare the efficacy of Suprascapular nerve block for chronic shoulder pain using placebo (normal Saline), only Bupvicain and Bupvicain +methyl prednisolone, in terms of pain relief, duration of relief and improvement in range of movements. Methods and materials: 90 cases with chronic shoulder pain were evaluated clinically and radiologically. At random these cases were allotted three study groups. On randomized basis group of 30 cases were given 10ml of 0.5% bupivacaine, another 30 cases were given 10 ml of 0.5%bupivacaine and 40mg of methylprednisolone acetate and remaining 30 were given .9% normal saline as placebo to block the suprascapular nerve as an outpatient procedure. Cases were followed up on 2nd, 7th, 21st and 90 days for range of movements and for pain according to VAS score. Results: Evaluation of the efficacy of the block was compared by verbal pain scores and improvement of range of movement in % at 2 days, 7 days, 21days and 3 months after the injection. Maximum improvement is noted with bupivacaine+methyl for suprascapular nerve block in cases of chronic shoulder pain. Conclusion: Suprascapular nerve block is safe, effective and well tolerated treatment for patient with chronic shoulder pain. Study group with mixed drug of bupivacaine and methyl prednisolone is most effective. .
Key words: Chronic shoulder pain, Suprascapular nerve block, Bupivacaine, Methylprednisolone acetate, Placebo (normal saline). References: 1.Pope D Croft P et al. Prevalence of shoulder pain in the community: the influence of case definition. Ann Rheum Dis 1997;56:308-12.
.Chakravarty KK, Webley M. Disorders of the shoulder: an often unrecognized cause of disability in elderly people. BMJ 1990;300:848–9.
3.Ritchie ED, Tong D, Chung F, Norris AM, Miniaci A, Vairavanathan SD. Suprascapular nerve block for postoperative pain relief in arthroscopic surgery: a new modality? Anesth Analg 1997;84:1306–12.
4.Gray H. Anatomy: descriptive and applied. 30th ed. London: Longmans, Green and Co, 1949:1123–4.
5.Emery P, Wedderburn L, Grahame R. Suprascapular nerve block for shoulder pain in rheumatoid arthritis. BMJ 1989;299:1079–80.
6.Brown DE, James DC, Roy S. Pain relief by suprascapular nerve block in glenohumeral arthritis. Scand J Rheumatol 1988;17:411–5.
7.Green S, Buchbinder R, Glazier R, Forbes A. Systematic review of randomized controlled trials of interventions for painful shoulder: selection criteria, outcome assessment, and efficacy. BMJ 1998;316:354–60.
8.Van der Heijden GJ, van der Windt DA, Kleijnen J, Koes BW, Bouter LM. Steroid injections for shoulder disorders: a systematic review of randomized clinical trials. Br J Gen Pract 1996;46:309–16.
9.Van der Winddt DA, van der Heijden GJ, Scholten RJ, Koes BW, Bouter LM. The efficacy of non-steroidal anti-inflammatory drugs (NSAIDS) for shoulder complaints. A systematic review. J Clin Epidemiol 1995;48:691–704.
10.Dangoisse MJ, Wilson DJ, Glynn CJ. MRI and clinical study of an easy safe technique of suprascapular nerve blockade. Acta Anaesth Belg 1994;45:49–54.
11.Gado K, Emery P. Modified suprascapular nerve block with bupivacaine alone effectively controls chronic shoulder pain in cases with rheumatoid arthritis. Ann Rheum Dis 1993;52:215–8.
12.Woolf CJ. Somatic pain pathogenesis and prevention. Br. J Anaesth 1995;75;169-76.
13.Lewis RN. The use of combined suprascapular and circumflex nerve blocks in management of chronic arthritis of the shoulder joint. Eur Acad Anaesth 1999;16;37-41.
14.Shanahan EM, Ahern M, Smith M, Wetherall M, Suprascapular nerve block (using bupivacaine and methylprednisolone acetate) in chronic shoulder pain. Ann Rheum Dis. 2003 May;62(5):400-6.
15.Lewis RN. The use of combined suprascapular and circumflex nerve blocks in management of chronic arthritis of shoulder joint. Eur Acad Anaesth 1999;16;37-41.
Copyright © 2013 Salgia Anil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article:-
Leila Ksiaa Cheikhrouhou (MD), Yousr Lakhoua Gorgi (phD), Salwa Jendoubi Ayed (MD), Houda Aouadi (MD) , Imen Sfar (MD), Mouna Makhlouf (MD), Taieb Ben Abdallah (phD), Khaled Ayed (phD).
Immunology Research Laboratory of Kidney Transplantation and Immunopathology (Laboratoire de Recherche: LR03SP01). University Tunis El Manar; Charles Nicolle Hospital. Tunisia.
Abstract:-
The aim of this study was to investigate the possibility of a significant relationship between the spontaneous clearance or the persistence of HCV infection and chemokines , chemokine receptors, cytokines and apoptosis genes polymorphisms in Tunisian hemodialysed patients. The polymorphisms of genes: CCR5 Δ32, CCR5 (-59029) A/G, CCR2 (64Ile), and MCP-1(-2518) A/G, (-889) IL-1α, (-511) and (+3954) IL-1β, IL-1-Ra, IL-18 (-137) and (-607), IL-12p40 (-1188) and Apo1/Fas (-670) were determined by PCR-RFLP, PCR-SSP and PCR-VNTR, at healthy blood donors (100 for cytokines and apo/fas gene polymorphisms and 170 for chemokine gene polymorphisms) and 100 hemodialysed patients infected by the HCV. Patients were classified in two groups: G1 included 76 active chronic hepatitis patients (positive RNA-HCV) and G2 included 24 having eliminated spontaneously virus (negative RNA-HCV). The univariate analyze of the genotypes and alleles frequencies of the cytokines polymorphisms studied does not reveal any positive or negative association statistically significant with the outcome of the HCV infection. Nevertheless, the frequency of genotype association [-37GC/-607CA] IL-18 is statistically higher among G2 patients (41,7%) compared to that at G1 hemodialysed (15,8%) (p=0,008, OR: 0.26, 95%CI: [0.10-0.73]). We found also, a significant increased frequency of AA genotype of Apo1/Fas gene in G2 patients (41,6%) than in G1 (17,5%) (p=0,026, OR=3,49, 95% CI [1,13-10,69]). Adjustment for known covariates factors (age, gender and genotypes) confirmed these univariate findings and revealed that the genotype association GC-CA of (-137and-607) IL-18 gene and AA genotype of Apo1/Fas gene were associated to the clearance of HCV (p=0.041 and p=0.017 respectively). Our results showed also a statistically increased frequencies of the CCR2 (64Ile) and the (-59029) CCR5 A alleles in total patients HCV infected (22,1% and 35,9%) and in G1 (24,3% and 40,6%) compared to controls (14,4% and 20%)[p=0.0086, p=0.03 and p=0.04, p=0.017 respectively]. Also, we observe a lower frequency of the MCP-1 G allele and a greater frequency of the CCR5 Δ32 variant in G2 (15,2% and 6,5%) compared to G1(22,6% and 1,4%)[p>0.05], but adjustment for known covariates factors didn’t confirmed these univariate findings. In conclusion, our study suggests a possible role of some of the chemokine and cytokine and apo/fas polymorphisms studied in the outcome of HCV infection in Tunisian population. These results should be further investigated by large population-based studies.
Key words:- Hepatitis C virus, Spontaneous clearance, Chemokines, Chemokines Receptors genes polymorphisms, cytokines, apo/fas polymorphisms.
Copyright © 2013 Leila K Cheikhrouho et al., This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.